                         SEQUENCE LISTING

<110>  TCER Oncology AB
 
<120>  IMMUNOTHERAPY

<130>  P032465WO

<150>  GB2010095.4
<151>  2020-07-01

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  141
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Construct design of neoantigenic construct #1

<400>  1

Val Pro Leu Gln Ser Leu Thr Gly Glu Val Phe Ala His Ala Ser Leu 
1               5                   10                  15      


Phe Val His Val Ala Gly Gly Ser Ala Thr Ser Gln Phe Lys Gly Tyr 
            20                  25                  30          


Arg Arg Lys Ser Ser Leu Asn Gly Lys Gly Glu Ser Ser Gly Gly Ser 
        35                  40                  45              


Ala Ile Tyr Glu Val Pro Lys Glu Met His Glu Asn Lys Gln His Leu 
    50                  55                  60                  


Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp Arg Glu Phe Gln Phe Phe 
65                  70                  75                  80  


Asp His Asn Leu Met Glu Ser Ile Lys Met Gly Asp Pro Gly Gly Ser 
                85                  90                  95      


Gly Gln Thr Ala Ile Asp Ala Ala Leu Thr Phe Val Val Asp Gln Asp 
            100                 105                 110         


Gly Gly Val His Ile Gly Gly Ser Met Pro Ile Gly Arg Ile Ala Asp 
        115                 120                 125             


Cys Arg Val Leu Trp Asp Tyr Val Tyr Gln Leu Leu Ser 
    130                 135                 140     


<210>  2
<211>  141
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Construct design of neoantigenic construct #2

<400>  2

Val Pro Leu Gln Ser Leu Thr Gly Glu Val Phe Ala His Ala Ser Leu 
1               5                   10                  15      


Phe Val His Val Ala Gly Gly Ser Ala Thr Ser Gln Phe Lys Gly Tyr 
            20                  25                  30          


Arg Arg Lys Ser Ser Leu Asn Gly Lys Gly Glu Ser Ser Gly Gly Ser 
        35                  40                  45              


Ala Ile Tyr Glu Val Pro Lys Glu Met His Glu Asn Lys Gln His Leu 
    50                  55                  60                  


Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp Arg Glu Phe Gln Phe Phe 
65                  70                  75                  80  


Asp His Asn Leu Met Glu Ser Ile Lys Met Gly Asp Pro Gly Gly Ser 
                85                  90                  95      


Ala Ser Pro Leu Lys Ser Ile Trp Ser Val Leu Thr Pro Ser Pro Ile 
            100                 105                 110         


Lys Ser Thr Leu Gly Gly Gly Ser Met Pro Ile Gly Arg Ile Ala Asp 
        115                 120                 125             


Cys Arg Val Leu Trp Asp Tyr Val Tyr Gln Leu Leu Ser 
    130                 135                 140     


<210>  3
<211>  189
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Neoantigenic construct #1

<400>  3

Met Lys Ala Ile Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys 
1               5                   10                  15      


Gly Ser Trp Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly 
            20                  25                  30          


Ser Lys Gly Gly Ser Ala Val Pro Leu Gln Ser Leu Thr Gly Glu Val 
        35                  40                  45              


Phe Ala His Ala Ser Leu Phe Val His Val Ala Gly Gly Ser Ala Thr 
    50                  55                  60                  


Ser Gln Phe Lys Gly Tyr Arg Arg Lys Ser Ser Leu Asn Gly Lys Gly 
65                  70                  75                  80  


Glu Ser Ser Gly Gly Ser Ala Ile Tyr Glu Val Pro Lys Glu Met His 
                85                  90                  95      


Glu Asn Lys Gln His Leu Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp 
            100                 105                 110         


Arg Glu Phe Gln Phe Phe Asp His Asn Leu Met Glu Ser Ile Lys Met 
        115                 120                 125             


Gly Asp Pro Gly Gly Ser Gly Gln Thr Ala Ile Asp Ala Ala Leu Thr 
    130                 135                 140                 


Phe Val Val Asp Gln Asp Gly Gly Val His Ile Gly Gly Ser Met Pro 
145                 150                 155                 160 


Ile Gly Arg Ile Ala Asp Cys Arg Val Leu Trp Asp Tyr Val Tyr Gln 
                165                 170                 175     


Leu Leu Ser Ser Gly His His His His His His His His 
            180                 185                 


<210>  4
<211>  189
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Neoantigenic construct #2

<400>  4

Met Lys Ala Ile Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys 
1               5                   10                  15      


Gly Ser Trp Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly 
            20                  25                  30          


Ser Lys Gly Gly Ser Ala Val Pro Leu Gln Ser Leu Thr Gly Glu Val 
        35                  40                  45              


Phe Ala His Ala Ser Leu Phe Val His Val Ala Gly Gly Ser Ala Thr 
    50                  55                  60                  


Ser Gln Phe Lys Gly Tyr Arg Arg Lys Ser Ser Leu Asn Gly Lys Gly 
65                  70                  75                  80  


Glu Ser Ser Gly Gly Ser Ala Ile Tyr Glu Val Pro Lys Glu Met His 
                85                  90                  95      


Glu Asn Lys Gln His Leu Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp 
            100                 105                 110         


Arg Glu Phe Gln Phe Phe Asp His Asn Leu Met Glu Ser Ile Lys Met 
        115                 120                 125             


Gly Asp Pro Gly Gly Ser Ala Ser Pro Leu Lys Ser Ile Trp Ser Val 
    130                 135                 140                 


Leu Thr Pro Ser Pro Ile Lys Ser Thr Leu Gly Gly Gly Ser Met Pro 
145                 150                 155                 160 


Ile Gly Arg Ile Ala Asp Cys Arg Val Leu Trp Asp Tyr Val Tyr Gln 
                165                 170                 175     


Leu Leu Ser Ser Gly His His His His His His His His 
            180                 185                 


<210>  5
<211>  189
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Wild-type antigenic construct #1

<400>  5

Met Lys Ala Ile Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys 
1               5                   10                  15      


Gly Ser Trp Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly 
            20                  25                  30          


Ser Lys Gly Gly Ser Ala Val Pro Leu Gln Ser Leu Thr Gly Glu Val 
        35                  40                  45              


Leu Ala His Ala Ser Leu Phe Val His Val Ala Gly Gly Ser Ala Thr 
    50                  55                  60                  


Ser Gln Phe Lys Gly Tyr Arg Arg Arg Ser Ser Leu Asn Gly Lys Gly 
65                  70                  75                  80  


Glu Ser Ser Gly Gly Ser Ala Ile Tyr Glu Val Pro Lys Glu Met His 
                85                  90                  95      


Gly Asn Lys Gln His Leu Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp 
            100                 105                 110         


Arg Glu Phe Gln Phe Phe Asp His His Leu Met Glu Ser Ile Lys Met 
        115                 120                 125             


Gly Asp Pro Gly Gly Ser Gly Gln Thr Ala Ile Asp Ala Ala Leu Thr 
    130                 135                 140                 


Ser Val Val Asp Gln Asp Gly Gly Val His Ile Gly Gly Ser Met Pro 
145                 150                 155                 160 


Ile Gly Arg Ile Ala Asp Cys Arg Leu Leu Trp Asp Tyr Val Tyr Gln 
                165                 170                 175     


Leu Leu Ser Ser Gly His His His His His His His His 
            180                 185                 


<210>  6
<211>  189
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Wild-type antigenic construct #2

<400>  6

Met Lys Ala Ile Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys 
1               5                   10                  15      


Gly Ser Trp Gly Ser Lys Gly Gly Ser Lys Gly Gly Ser Lys Gly Gly 
            20                  25                  30          


Ser Lys Gly Gly Ser Ala Val Pro Leu Gln Ser Leu Thr Gly Glu Val 
        35                  40                  45              


Leu Ala His Ala Ser Leu Phe Val His Val Ala Gly Gly Ser Ala Thr 
    50                  55                  60                  


Ser Gln Phe Lys Gly Tyr Arg Arg Arg Ser Ser Leu Asn Gly Lys Gly 
65                  70                  75                  80  


Glu Ser Ser Gly Gly Ser Ala Ile Tyr Glu Val Pro Lys Glu Met His 
                85                  90                  95      


Gly Asn Lys Gln His Leu Gln Lys Asp Phe Phe Gly Gly Ser Ala Asp 
            100                 105                 110         


Arg Glu Phe Gln Phe Phe Asp His His Leu Met Glu Ser Ile Lys Met 
        115                 120                 125             


Gly Asp Pro Gly Gly Ser Ala Ser Pro Leu Lys Ser Ile Trp Ser Val 
    130                 135                 140                 


Ser Thr Pro Ser Pro Ile Lys Ser Thr Leu Gly Gly Gly Ser Met Pro 
145                 150                 155                 160 


Ile Gly Arg Ile Ala Asp Cys Arg Leu Leu Trp Asp Tyr Val Tyr Gln 
                165                 170                 175     


Leu Leu Ser Ser Gly His His His His His His His His 
            180                 185                 


<210>  7
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ETV6 neoantigen

<400>  7

Val Leu Trp Asp Tyr Val Tyr Gln Leu 
1               5                   


<210>  8
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NUP210 neoantigen

<400>  8

Ala Ile Asp Ala Ala Leu Thr Phe Val 
1               5                   


<210>  9
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  NUP210 wild-type

<400>  9

Ala Ile Asp Ala Ala Leu Thr Ser Val 
1               5                   


<210>  10
<211>  9
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  ETV6 wild-type

<400>  10

Leu Leu Trp Asp Tyr Val Tyr Gln Leu 
1               5                   


